N-tert-butyl-2-methylnicotinamide | 923563-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-tert-butyl-2-methylnicotinamide
• 英文别名: N-tert-Butyl-2-methylpyridine-3-carboxamide
• CAS: 923563-42-2
• 化学式: C₁₁H₁₆N₂O
• 分子量: 192.261
• InChiKey: RPNURTLMTRIZDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [(R)-2-(2-fluoro-phenyl)-1-(methoxy-methyl-carbamoyl)-ethyl]-carbamic acid tert-butyl ester 、 N-tert-butyl-2-methylnicotinamide 生成 [(R)-1-(2-fluoro-benzyl)-3-(3-isopropylcarbamoyl-pyridin-2-yl)-2-oxo-propyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors

  摘要：

  本发明涉及公式（I）的化合物或其药学上可接受的盐；其中A为（1）；X选自CH，CF和N；R5选自H，C1-C6氟烷基和—OR12；R9选自H，—NR13C（O）R14和—C（O）NR10R11；R12选自H，C1-C6烷基和C3-C6环烷基，用作DPP-IV酶的抑制剂，用于治疗或预防包括2型糖尿病在内的疾病。

  公开号：

  US20080214616A1
• 作为产物：
  描述：

  叔丁胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 乙腈 、 二氯甲烷 为溶剂， 反应 16.5h， 生成 N-tert-butyl-2-methylnicotinamide
  参考文献：
  名称：

  WO2007/15767

  摘要：

  公开号：

文献信息

• Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors
  申请人：Blaszczak Larry Chris

  公开号：US20080214616A1

  公开（公告）日：2008-09-04

  The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C 1 -C 6 fluoroalkyl, and —OR12; R9 is selected from H —NR13C(O)R14 and —C(O)NR10R11; R12 is selected from H, C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.

  本发明涉及公式（I）的化合物或其药学上可接受的盐；其中A为（1）；X选自CH，CF和N；R5选自H，C1-C6氟烷基和—OR12；R9选自H，—NR13C（O）R14和—C（O）NR10R11；R12选自H，C1-C6烷基和C3-C6环烷基，用作DPP-IV酶的抑制剂，用于治疗或预防包括2型糖尿病在内的疾病。
• Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors
  作者：Erik L. Meredith、Ophelia Ardayfio、Kimberly Beattie、Markus R. Dobler、Istvan Enyedy、Christoph Gaul、Vinayak Hosagrahara、Charles Jewell、Keith Koch、Wendy Lee、HansJoerg Lehmann、Timothy A. McKinsey、Karl Miranda、Nikos Pagratis、Margaret Pancost、Anup Patnaik、Dillon Phan、Craig Plato、Ming Qian、Vasumathy Rajaraman、Chang Rao、Olga Rozhitskaya、Thomas Ruppen、Jie Shi、Sarah J. Siska、Clayton Springer、Maurice van Eis、Richard B. Vega、Anette von Matt、Lihua Yang、Taeyoung Yoon、Ji-Hu Zhang、Na Zhu、Lauren G. Monovich

  DOI：10.1021/jm100075z

  日期：2010.8.12

  A novel 2,6-naphthyridine was identified by high throughput screen (HTS) as a dual protein kinase C/D (PKC/PKD) inhibitor. PKD inhibition in the heart was proposed as a potential antihypertrophic mechanism with application as a heart failure therapy. As PKC was previously identified as the immediate upstream activator of PKD, PKD vs PKC selectivity was essential to understand the effect of PKD inhibition in models of cardiac hypertrophy and heart failure. The present study describes the modification of the HTS hit to a series of prototype pan-PKD inhibitors with routine 1000-fold PKD vs PKC selectivity. Example compounds inhibited PKD activity in vitro, in cells, and in vivo following oral administration. Their effects on heart morphology and function are discussed herein.
• PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1912946B1

  公开（公告）日：2009-05-27
• US8133907B2
  申请人：——

  公开号：US8133907B2

  公开（公告）日：2012-03-13
• [EN] PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINE EN TANT QU'INHIBITEURS DE DIPEPTEDYL PEPTIDASE
  申请人：LILLY CO ELI

  公开号：WO2007015767A1

  公开（公告）日：2007-02-08

  [EN] The present invention is directed to compounds of formula (I) or a pharmaceutically acceptable salt thereof; wherein A is (1); X is selected from CH, CF and N; R5 is selected from H, C₁-C₆ alkyl, C₁-C₆ fluoroalkyl, and -OR12; R9 is selected from H -NR13C(O)R14 and -C(O)NR10R11; R12 is selected from H, C₁-C₆ alkyl and C₃-C₆ cycloalkyl, for use as inhibitors of the DPP-IV enzyme in the treatment or prevention of conditions including Type II diabetes.
  [FR] La présente invention concerne des composés de formule I : ou un sel pharmaceutiquement acceptable de ceux-ci ; dans laquelle A est égal à X est choisi parmi CH, CF et N ; R5 est choisi parmi H, C₁-C₆ alkyle, C₁-C₆ fluoroalkyle, et -OR12 ; R9 est choisi parmi H -NR13C(O)R14 et -C(O)NRlORl 1 ; R12 est choisi parmi H, C₁-C₆ alkyle et C₃-C₆ cycloalkyle, pour une utilisation comme inhibiteurs de l'enzyme DPP-IV dans le traitement ou la prévention de maladies comprenant le diabète de Type II.